ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.

Autor: Zhou J; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Yiying Quah J; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Ng Y; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Chooi JY; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore., Hui-Min Toh S; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Lin B; Department of Hematology-Oncology, National University Cancer Institute, Republic of Singapore., Zea Tan T; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Hosoi H; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Osato M; Cancer Science Institute of Singapore, Department of Pediatrics, National University of Singapore., Seet Q; ASLAN Pharmaceuticals, Republic of Singapore., Ooi LAG; ASLAN Pharmaceuticals, Republic of Singapore., Lindmark B; ASLAN Pharmaceuticals, Republic of Singapore., McHale M; ASLAN Pharmaceuticals, Republic of Singapore., Chng WJ; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore.

Publikováno v: Haematologica [Haematologica] 2020 Sep 01; Vol. 105 (9), pp. 2286-2297. Date of Electronic Publication: 2020 Sep 01.